Endometrial histologic changes in post-menopausal breast cancer patients using tamoxifen

Int J Gynaecol Obstet. 2001 Dec;75(3):257-62. doi: 10.1016/s0020-7292(01)00476-3.

Abstract

Objective: The aim of this study was to evaluate the effect of tamoxifen on the endometrium of post-menopausal women with breast cancer and to examine the relationship between ultrasonography, hysteroscopy and histopathologic changes.

Method: Included in this longitudinal study were 303 post-menopausal women taking 20 mg daily of tamoxifen. Hysteroscopy was performed in 83 patients with an endometrial thickness of only >or=5 mm and 34 with vaginal bleeding also. Forty-five asymptomatic patients (control group) underwent hysteroscopies.

Result: The most frequent outcome in patients with endometrial thickness of only >or=5 mm was an atrophic endometrium in an empty cavity (79.5%) whereas simple hyperplasia (35.3%) was found in women with vaginal bleeding. Carcinoma was diagnosed in seven cases (5.9%). In the control group, no endometrial cancer was found.

Conclusion: This study suggests that patients with a thickness >5 mm should be offered a whole hysteroscopic evaluation, whenever bleeding is reported.

Publication types

  • Clinical Trial

MeSH terms

  • Aged
  • Antineoplastic Agents, Hormonal / adverse effects*
  • Antineoplastic Agents, Hormonal / therapeutic use*
  • Atrophy / chemically induced
  • Atrophy / pathology
  • Breast Neoplasms / drug therapy*
  • Endometrial Hyperplasia / chemically induced
  • Endometrial Hyperplasia / pathology
  • Endometrial Neoplasms / chemically induced
  • Endometrial Neoplasms / pathology*
  • Endometrium / diagnostic imaging
  • Endometrium / drug effects*
  • Endometrium / pathology*
  • Female
  • Humans
  • Hysteroscopy
  • Longitudinal Studies
  • Middle Aged
  • Myoma / chemically induced
  • Myoma / pathology*
  • Postmenopause / drug effects*
  • Tamoxifen / adverse effects*
  • Tamoxifen / therapeutic use*
  • Ultrasonography

Substances

  • Antineoplastic Agents, Hormonal
  • Tamoxifen